Serious Shortage Protocol (SSP) for Lipitor® chewable tablets 20mg

The Department of Health and Social Care has issued a Serious Shortage Protocol (SSP) for Lipitor® chewable tablets 20mg (SSP013)

The Department of Health and Social Care (DHSC) has issued a Serious Shortage Protocol (SSP) following a significant ongoing disruption to the supply of Lipitor® chewable tablets 20mg (SSP013). Community pharmacies in England and Wales are expected to implement SSP013 with immediate effect.   SSP013 came into effect on Thursday 18 November 2021 SSP013 expires on Wednesday 12 January 2022 Under SSP013, when presented with a prescription for Lipitor® chewable tablets 20mg pharmacists can instead supply one atorvastatin tablet 20mg for each Lipitor® chewable tablet 20mg   Recommended actions and advice for pharmacy teams: Ensure the currentversion of the SSP is used before supplying the alternative item Ensure that all staff, including locums, who will be involved in dispensing an item in accordance with an SSP are trained and competent to do so Ensure that an SSP standard operating procedure (SOP) is in place and other relevant SOPs are updated, read, understood, signed and implemented by all members of the pharmacy team involved in service delivery Ensure that the pharmacy team know where they can find new SSPs and/or changes to an existing SSP Ensure that the pharmacy has access to an NHSmail account so that it can receive notification when an SSP is issued Patients should be referred to their prescriber where the patient is unsuitable for inclusion or a non-chewable atorvastatin tablet is not appropriate   Professional indemnity insurance NPA professional indemnity insurance will cover NPA members, customers (and the pharmacists they employ/engage) when supplying medicines/appliances under the relevant enabling legislation and the Serious Shortages Protocols (SSPs) which apply.…

New endorsement for Serious Shortage Protocols (SSPs) (updated 12 November 2021)

A new endorsement for Serious Shortage Protocols (SSPs) has been introduced from 1 June 2021. The transition period for implementation of the new endorsement has been extended until February 2022.

The Department of Health and Social Care (DHSC) has introduced a new endorsement to claim for supplies made under a Serious Shortage Protocol (SSPs) from 1 June 2021. The new endorsement uses the code ‘SSP’ and the three digit reference number that is specific to the SSP. Full details of the arrangements of the new SSP endorsement can be found in the June 2021 Drug Tariff Part II Clause 9E.   Key points for pharmacy teams Contractors should start using the new endorsement functionality to claim for supplies made under a SSP from 1 June 2021, where available Update 12/11/21: A transition period from 1 June 2021 to 5 October 2021 was initially implemented to allow contractors to continue to use the existing ‘NCSO’ endorsement where the functionality for the new endorsement is not yet available, however, this has now been extended until February 2022 (to include January 2022 prescriptions) From 5 February 2022, the NCSO endorsement will no longer be accepted During the transition period, the NHS Business Services Authority (NHSBSA) will accept either the existing ‘NCSO’ or the new ‘SSP’ endorsement for any SSP claims The new SSP endorsement will only be accepted for electronic and paper prescriptions after the transition period has ended SSP claims made using EPS tokens after February 2022 will not be accepted for payment – claims for electronic prescriptions are to be made electronically For multiple dispensed product SSP (where a prescribed item is replaced by two or more items): some systems may allow the new SSP endorsement for both replacement items, whilst other systems may only allow the endorsement for one replacement item Where only one item can be endorsed, the NHSBSA will add and reimburse for the other replacement items The SSP endorsement guidance also applies to replacement items which are not listed in Part VIII of the Drug Tariff   The new update will affect all future SSPs including the following existing SSPs: SSP05: Fluoxetine 10mg tablets due to expire 11 February 2022 Prescriptions for SSP05 should be endorsed SSP05 SSP007: Fluoxetine 30mg capsules due to expire 13 August 2021 SSP012: Estradot 75 microgram patches due to expire 11 June 2021   Please note, the SSPs can be amended or revoked at any time.…